Results 91 to 100 of about 1,252,619 (143)

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates. [PDF]

Pharm Res, 2022
Aoyama M, Tada M, Yokoo H, Demizu Y, Ishii-Watabe A.   +4 more
europepmc   +1 more source

Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy. [PDF]

Immunity
Cheng BY, Centeio RM, Chiu DK, Kiyohara CL, Herzog E, Dahan R, Thomas WE, Wang TT.   +7 more
europepmc   +1 more source

Mechanisms and targets of Fcγ-receptor mediated immunity to malaria sporozoites. [PDF]

Nat Commun, 2021
Feng G, Wines BD, Kurtovic L, Chan JA, Boeuf P, Mollard V, Cozijnsen A, Drew DR, Center RJ, Marshall DL, Chishimba S, McFadden GI, Dent AE, Chelimo K, Boyle MJ, Kazura JW, Hogarth PM, Beeson JG.   +17 more
europepmc   +1 more source

Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy. [PDF]

Rheumatology (Oxford)
Freitag M, Kolb P, Falcone V, Claus M, Schröder P, Andreeva I, Rodon L, Ewald M, Deicher FS, Stütz AN, Distler JHW, Blank N, Grieshaber-Bouyer R, Muñoz LE, Lorenz HM, Schett G, Merkt W.   +16 more
europepmc   +1 more source

A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment. [PDF]

Biomedicines, 2021
Wu CC, Chiang CY, Liu SJ, Chen HW.
europepmc   +1 more source

Author Correction: GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region. [PDF]

Nat Commun
Ishikawa Y, Tanaka N, Asano Y, Kodera M, Shirai Y, Akahoshi M, Hasegawa M, Matsushita T, Saito K, Motegi SI, Yoshifuji H, Yoshizaki A, Kohmoto T, Takagi K, Oka A, Kanda M, Tanaka Y, Ito Y, Nakano K, Kasamatsu H, Utsunomiya A, Sekiguchi A, Niiro H, Jinnin M, Makino K, Makino T, Ihn H, Yamamoto M, Suzuki C, Takahashi H, Nishida E, Morita A, Yamamoto T, Fujimoto M, Kondo Y, Goto D, Sumida T, Ayuzawa N, Yanagida H, Horita T, Atsumi T, Endo H, Shima Y, Kumanogoh A, Hirata J, Otomo N, Suetsugu H, Koike Y, Tomizuka K, Yoshino S, Liu X, Ito S, Hikino K, Suzuki A, Momozawa Y, Ikegawa S, Tanaka Y, Ishikawa O, Takehara K, Torii T, Sato S, Okada Y, Mimori T, Matsuda F, Matsuda K, Amariuta T, Imoto I, Matsuo K, Kuwana M, Kawaguchi Y, Ohmura K, Terao C.   +71 more
europepmc   +1 more source

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. [PDF]

Blood Adv, 2021
Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trněný M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS.   +22 more
europepmc   +1 more source

Glycan pairing in therapeutic IgG orchestrates Fcγ receptor engagement and ADCC: an integrated structure-function approach for thorough evaluation of Fc N-glycans as critical quality attributes. [PDF]

MAbs
Meudt M, Baumeister J, Russell AC, Dzielak L, Hansen G, Mizaikoff B, Ebert S, Rosenau F, Blech M, Higel F.   +9 more
europepmc   +1 more source

Inhibitory Fcγ Receptor and Paired Immunoglobulin Type 2 Receptor Alpha Genotypes in Alzheimer's Disease. [PDF]

J Alzheimers Dis, 2021
Pandey JP, Namboodiri AM, Nietert PJ, Barnes LL, Bennett DA.   +4 more
europepmc   +1 more source

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy. [PDF]

Res Pract Thromb Haemost
Kartika T, Buitrago L, Li J, Cunningham-Rundles C, Coller BS.   +4 more
europepmc   +1 more source